MedTrace Logo

Treatment of Moderate to Severe Refractory Crohn's Disease

NCT06721962 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-12-10

No results posted yet for this study

Summary

This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.

Conditions

  • Crohns Disease

Interventions

BIOLOGICAL

TRX103

TRX103 is an investigational research product that may treat and provide long term relief to individuals suffering from Crohn's Disease.

DRUG

Cyclophosphamide

Low dose cyclophosphamide conditioning.

Sponsors & Collaborators

  • Tr1X, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2026-01-30
Completion
2027-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06721962 on ClinicalTrials.gov